Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPARα expression

Gut

Volumn 65, Issue 11, 2016, Pages 1882-1894

  Loyer, Xavier ^a,b   Paradis, Valérie ^b,c,d   Hénique, Carole ^a,b   Vion, Anne Clémence ^a,b   Colnot, Nathalie ^c   Guerin, Coralie L ^a,b   Devue, Cécile ^a,b   On, Sissi ^a,b   Scetbun, Jérémy ^a,b   Romain, Mélissa ^a,b   Paul, Jean Louis ^e   Rothenberg, Marc E ^f   Marcellin, Patrick ^b,c,d   Durand, Francois ^b,c,d   Bedossa, Pierre ^b,c,d   Prip Buus, Carina ^b,g,h   Baugé, Eric ⁱ   Staels, Bart ⁱ   Boulanger, Chantal M ^a,b   Tedgui, Alain ^a,b   Rautou, Pierre Emmanuel ^a,b,c   more..

^a PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c BEAUJON HOSPITAL   (France)

^d CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^g INSTITUT COCHIN   (France)

^h CNRS   (France)

ⁱ UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTAGOMIR; ANTAGOMIR 21; LIVER PROTECTIVE AGENT; LOW DENSITY LIPOPROTEIN RECEPTOR; MICRORNA 21; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; UNCLASSIFIED DRUG; LOW DENSITY LIPOPROTEIN; MICRORNA; MIRN21 MICRORNA, MOUSE; OLIGONUCLEOTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; EXPERIMENTAL MODEL; GENE EXPRESSION; HEPATITIS; HUMAN; HUMAN TISSUE; LIPID DIET; LIPID STORAGE; LIVER CELL DAMAGE; LIVER FIBROSIS; LIVER PROTECTION; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; WILD TYPE; ANIMAL; ANTAGONISTS AND INHIBITORS; GENE EXPRESSION PROFILING; LIPID METABOLISM; LIVER CELL; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; PROCEDURES;

ANIMALS; DIET, HIGH-FAT; GENE EXPRESSION PROFILING; HEPATOCYTES; HUMANS; LIPID METABOLISM; LIPOPROTEINS, LDL; MICE; MICRORNAS; NON-ALCOHOLIC FATTY LIVER DISEASE; OLIGONUCLEOTIDES; PPAR ALPHA;

EID: 84940901740     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-308883     Document Type: Article

References (49)

1. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55:2005-23.
2. Ratziu V, Bellentani S, Cortez-Pinto H, et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010;53:372-84.
3. Weston SR, Leyden W, Murphy R, et al. Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology 2005;41:372-9.
4. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009;136:215-33.
5. Wang XW, Heegaard NH, Orum H. MicroRNAs in liver disease. Gastroenterology 2012;142:1431-43.
6. Szabo G, Sarnow P, Bala S. MicroRNA silencing and the development of novel therapies for liver disease. J Hepatol 2012;57:462-6.
7. Cheung O, Puri P, Eicken C, et al. Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology 2008;48:1810-20.
8. Dattaroy D, Pourhoseini S, Das S, et al. Micro-RNA 21 inhibition of SMAD7 enhances fibrogenesis via leptin-mediated NADPH oxidase in experimental and human nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2015;308:G298-312.
9. Wang B, Majumder S, Nuovo G, et al. Role of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice. Hepatology 2009;50:1152-61.
10. da Costa Martins PA, Salic K, Gladka MM, et al. MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling. Nat Cell Biol 2010;12:1220-7.
11. Loyer X, Potteaux S, Vion AC, et al. Inhibition of microRNA-92a prevents endothelial dysfunction and atherosclerosis in mice. Circ Res 2014;114:434-43.
12. Krutzfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005;438:685-9.
13. Lu TX, Hartner J, Lim EJ, et al. MicroRNA-21 limits in vivo immune response-mediated activation of the IL-12/IFN-gamma pathway, Th1 polarization, and the severity of delayed-type hypersensitivity. J Immunol 2011;187:3362-73.
14. Schaefer A, Jung M, Miller K, et al. Suitable reference genes for relative quantification of miRNA expression in prostate cancer. Exp Mol Med 2010;42:749-58.
15. Bonauer A, Carmona G, Iwasaki M, et al. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science 2009;324:1710-13.
16. Thum T, Gross C, Fiedler J, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008;456:980-4.
17. Bedossa P, Poitou C, Veyrie N, et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology 2012;56:1751-9.
18. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-21.
19. Bustin SA, Benes V, Garson JA, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009;55:611-22.
20. Vandesompele J, De Preter K, Pattyn F, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002;3:Research0034.
21. Williamson DH, Bates MW, Krebs HA. Activity and intracellular distribution of enzymes of ketone-body metabolism in rat liver. Biochem J 1968;108:353-61.
22. Francque S, Verrijken A, Caron S, et al. PPARalpha gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis. J Hepatol 2015;63:164-73.
23. Yeon JE, Choi KM, Baik SH, et al. Reduced expression of peroxisome proliferator-activated receptor-alpha may have an important role in the development of non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2004;19:799-804.
24. Lefebvre P, Chinetti G, Fruchart JC, et al. Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest 2006;116:571-80.
25. Firrincieli D, Zuniga S, Poupon R, et al. Role of nuclear receptors in the biliary epithelium. Dig Dis 2011;29:52-7.
26. Cermelli S, Ruggieri A, Marrero JA, et al. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS ONE 2011;6:e23937.
27. Brunt EM, Tiniakos DG. Histopathology of nonalcoholic fatty liver disease. World J Gastroenterol 2010;16:5286-96.
28. Moschos SA, Williams AE, Perry MM, et al. Expression profiling in vivo demonstrates rapid changes in lung microRNA levels following lipopolysaccharide-induced inflammation but not in the anti-inflammatory action of glucocorticoids. BMC Genomics 2007;8:240.
29. Lu TX, Munitz A, Rothenberg ME. MicroRNA-21 is up-regulated in allergic airway inflammation and regulates IL-12p35 expression. J Immunol 2009;182:4994-5002.
30. Iliopoulos D, Malizos KN, Oikonomou P, et al. Integrative microRNA and proteomic approaches identify novel osteoarthritis genes and their collaborative metabolic and inflammatory networks. PLoS ONE 2008;3:e3740.
31. Sonkoly E, Wei T, Janson PC, et al. MicroRNAs: novel regulators involved in the pathogenesis of psoriasis PLoS ONE 2007;2:e610.
32. Wu F, Zikusoka M, Trindade A, et al. MicroRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2 alpha. Gastroenterology 2008;135:1624-35 e24.
33. Zhang Z, Li Z, Gao C, et al. miR-21 plays a pivotal role in gastric cancer pathogenesis and progression. Lab Invest 2008;88:1358-66.
34. Ji R, Cheng Y, Yue J, et al. MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation. Circ Res 2007;100:1579-88.
35. Cheng Y, Ji R, Yue J, et al. MicroRNAs are aberrantly expressed in hypertrophic heart: do they play a role in cardiac hypertrophy Am J Pathol 2007;170:1831-40.
36. Sheedy FJ, Palsson-McDermott E, Hennessy EJ, et al. Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nat Immunol 2010;11:141-7.
37. Thuy S, Ladurner R, Volynets V, et al. Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J Nutr 2008;138:1452-5.
38. Mouzaki M, Comelli EM, Arendt BM, et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology 2013;58:120-7.
39. Richardson MM, Jonsson JR, Powell EE, et al. Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. Gastroenterology 2007;133:80-90.
40. Zhou R, Hu G, Liu J, et al. NF-kappaB p65-dependent transactivation of miRNA genes following Cryptosporidium parvum infection stimulates epithelial cell immune responses. PLoS Pathog 2009;5:e1000681.
41. Vinciguerra M, Sgroi A, Veyrat-Durebex C, et al. Unsaturated fatty acids inhibit the expression of tumor suppressor phosphatase and tensin homolog (PTEN) via microRNA-21 up-regulation in hepatocytes. Hepatology 2009;49:1176-84.
42. Kakisaka K, Cazanave SC, Werneburg NW, et al. A hedgehog survival pathway in 'undead' lipotoxic hepatocytes. J Hepatol 2012;57:844-51.
43. Sarkar J, Gou D, Turaka P, et al. MicroRNA-21 plays a role in hypoxia-mediated pulmonary artery smooth muscle cell proliferation and migration. Am J Physiol Lung Cell Mol Physiol 2010;299:L861-71.
44. Zhou J, Wang KC, Wu W, et al. MicroRNA-21 targets peroxisome proliferators-activated receptor-alpha in an autoregulatory loop to modulate flow-induced endothelial inflammation. Proc Natl Acad Sci USA 2011;108:10355-60.
45. Pawlak M, Bauge E, Bourguet W, et al. The transrepressive activity of peroxisome proliferator-activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice. Hepatology 2014;60:1593-606.
46. Marx N, Kehrle B, Kohlhammer K, et al. PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res 2002;90:703-10.
47. Janssen HL, Reesink HW, Lawitz EJ, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med 2013;368:1685-94.
48. Kallwitz ER, McLachlan A, Cotler SJ. Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease. World J Gastroenterol 2008;14:22-8.
49. Staels B, Rubenstrunk A, Noel B, et al. Hepato-protective effects of the dual PPARalpha/delta agonist GFT505 in rodent models of NAFLD/NASH. Hepatology 2013;58:1941-52.